CD8A and acute myeloid leukemia: In AML patients experiencing relapse after prolonged post-HSCT remission, functionally impaired CD8+ T cells expressing IRs such as PD-1, CTLA-4, and TIM-3 accumulate in the tumor microenvironment (84).